Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study

Publication/Presentation Date

2-2022

Volume

82

Issue

4

First Page

14-03

Last Page

14-03

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Share

COinS